These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 8706040)

  • 1. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
    Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
    Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo studies of the new gonadotropin-releasing hormone antagonist--copolymer conjugates having antitumor activity.
    Vincze B; Pályi I; Gaál D; Pató J; Móra M; Mezõ I; Teplán I; Seprõdi J
    Cancer Detect Prev; 1996; 20(2):153-9. PubMed ID: 8706041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
    Teplán I
    Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
    Fister S; Günthert AR; Aicher B; Paulini KW; Emons G; Gründker C
    Cancer Res; 2009 Aug; 69(16):6473-81. PubMed ID: 19638591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
    Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of growth and proliferation of EcRG293 cell line expressing high-affinity gonadotropin-releasing hormone (GnRH) receptor under the control of an inducible promoter by GnRH agonist (D-Lys6)GnRH and antagonist (Antide).
    Kakar SS
    Cancer Res; 1998 Oct; 58(20):4558-60. PubMed ID: 9788600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, conformation, biodistribution, and hormone-related in vitro antitumor activity of a gonadotropin-releasing hormone antagonist-branched polypeptide conjugate.
    Mezö G; Mezö I; Pimm MV; Kajtár J; Seprödi J; Teplán I; Kovács M; Vincze B; Pályi I; Idei M; Szekerke M; Hudecz F
    Bioconjug Chem; 1996; 7(6):642-50. PubMed ID: 8950483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
    Nagy A; Schally AV
    Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
    Fister S; Günthert AR; Emons G; Gründker C
    Cancer Res; 2007 Feb; 67(4):1750-6. PubMed ID: 17308117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha.
    Wu HM; Cheng JC; Wang HS; Huang HY; MacCalman CD; Leung PC
    Cancer Res; 2009 May; 69(10):4202-8. PubMed ID: 19366794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.
    Castellón E; Clementi M; Hitschfeld C; Sánchez C; Benítez D; Sáenz L; Contreras H; Huidobro C
    Cancer Invest; 2006; 24(3):261-8. PubMed ID: 16809153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of gonadotropin-releasing hormone III analogs. Structure-antitumor activity relationships.
    Mezö I; Lovas S; Pályi I; Vincze B; Kálnay A; Turi G; Vadász Z; Seprödi J; Idei M; Tóth G; Gulyás E; Otvös F; Mák M; Horváth JE; Teplán I; Murphy RF
    J Med Chem; 1997 Oct; 40(21):3353-8. PubMed ID: 9341910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
    Gründker C; Völker P; Schulz KD; Emons G
    Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues.
    Borri P; Coronnello M; Noci I; Pesciullesi A; Peri A; Caligiani R; Maggi M; Torricelli F; Scarselli G; Chieffi O; Mazzei T; Mini E
    Gynecol Oncol; 1998 Dec; 71(3):396-403. PubMed ID: 9887238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
    Schubert A; Hawighorst T; Emons G; Gründker C
    Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
    Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M
    Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP.
    Ravenna L; Salvatori L; Morrone S; Lubrano C; Cardillo MR; Sciarra F; Frati L; Di Silverio F; Petrangeli E
    J Androl; 2000; 21(4):549-57. PubMed ID: 10901441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.